Immunotherapy-responsive gastric cancers identified.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

1. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.Cancer immunology, immunotherapy : CII · 2023
   Article
2. A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration.Cancer science · 2020
   Article
3. Dissection of gastric cancer heterogeneity for precision oncology.Cancer science · 2019
   Review

Corrections and comments

• Comment on
  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.2018

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as